AstraZeneca has defended its Covid-19 vaccine after several countries suspended its use over blood clot concerns this week.
The pharmaceutical giant said Friday that its analysis not only showed “no evidence of an increased risk” of blood clots in Oxford-AstraZeneca vaccine recipients, but a lower number than in the general population.
“An analysis of our safety data of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country with COVID-19 Vaccine AstraZeneca,” it said in a statement.
“In fact, the observed number of these types of events are significantly lower in those vaccinated than would be expected among the general population."
Thailand on Friday followed Denmark, Iceland and Norway in suspending the use of the Oxford-AstraZeneca vaccine while investigators probe potential side effects and adverse reactions.
AstraZeneca said it will fully support any ongoing investigations.